首页> 外文期刊>PM & R: the journal of injury, function, and rehabilitation >Efficacy and Safety of Hylan G-F 20 for Symptomatic Glenohumeral Osteoarthritis: A Prospective, Pilot Study
【24h】

Efficacy and Safety of Hylan G-F 20 for Symptomatic Glenohumeral Osteoarthritis: A Prospective, Pilot Study

机译:Hylan G-F 20对有症状的Glenohumeral骨关节炎的有效性和安全性:前瞻性,初步研究

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To determine the safety and efficacy of 2 intra-articular, fluoroscopically guided hylan G-F 20 injections for painful glenohumeral osteoarthritis. DeSign: This study was a prospective open-label pilot investigation with both U.S. Food and Drug Administration and institutional review board approval. Setting: Private, outpatient practice within a tertiary care, university medical school. Participants: Thirty-six subjects with moderate to severe glenohumeral osteoarthritis, with pain (visual analog scale [VAS] 40 mm or greater) despite following a 3-month standard, nonsurgical treatment program. Interventions: Two injections of 2 mL hylan G-F 20, under fluoroscopic guidance confirmed by arthrography, 2 weeks apart. No new treatments were allowed during the course of the study. Analgesics were discontinued 24 hours before visits. Main Outcome Measurements: Data collected were radiographs; rotator cuff integrity as determined with magnetic resonance imaging; VAS for pain at rest, at night, and with activity; and shoulder-related quality of life (Western Ontario Rotator Cuff Index [WORC]). Subjects were re-evaluated after each injection and at 6 weeks, 3 months, and 6 months. Changes from baseline for VAS and WORC were recorded in Excel and analyzed using SPSS. Intent-to-treat analysis was performed. The type and severity of adverse events were recorded. Results: Mean VAS at baseline was 63 mm (SD 14.5). Clinically >=20% improvement) and statistically significant improvements (P < .001) in VAS pain were seen at 6 weeks, 3 months, and 6 months. Mean improvement in WORC at 6 months was 16.5 (P < .01), with most gains in "lifestyle" and "emotion" questions. Age, gender, body mass index, and rotator cuff pathology did not correlate with response. Three subjects described heightened pain for a few days after injections. Three subjects reported greater pain at 6 months and were unsatisfied. Four experienced no effect of treatment. There were no inflammatory react...
机译:目的:确定两种关节腔内,透视引导下的hylan G-F 20注射剂治疗痛苦的肱肱骨骨关节炎的安全性和有效性。 DeSign:这项研究是美国食品药品监督管理局和机构审查委员会批准的前瞻性开放标签试验研究。地点:三级医疗大学医学院内的私人门诊诊所。参与者:36名患有中度至重度盂肱型骨关节炎的患者,尽管遵循了3个月的标准非手术治疗计划,但仍出现疼痛(视觉模拟评分[VAS] 40 mm或更大)。干预措施:在两次经关节造影证实的透视下,两次注射2 mL Hylan G-F 20。在研究过程中不允许新的治疗方法。拜访前24小时停用止痛药。主要结果测量:收集的数据为射线照相;磁共振成像确定的肩袖完整性; VAS用于休息,夜间和活动时的疼痛;与肩膀相关的生活质量(西安大略肩袖指数[WORC])。每次注射后以及第6周,第3个月和第6个月对受试者进行重新评估。在Excel中记录了VAS和WORC相对于基线的变化,并使用SPSS进行了分析。进行意向治疗分析。记录不良事件的类型和严重程度。结果:基线时的平均VAS为63毫米(标准差14.5)。在6周,3个月和6个月时,VAS疼痛的临床改善> = 20%)和统计学上显着改善(P <.001)。在6个月时,WORC的平均改善为16.5(P <.01),其中“生活方式”和“情绪”问题的获益最大。年龄,性别,体重指数和肩袖病理与反应无关。三名受试者描述了注射后几天疼痛加剧。三名受试者在6个月时报告疼痛加剧且不满意。四人均未见治疗效果。没有炎症反应...

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号